Mode
Text Size
Log in / Sign up
N/A N=104

Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement

Ventral Incisional Hernia

Enrolled (actual)
104
Serious AEs
2.9%
Results posted
Dec 2015
Primary outcome: Primary: Hernia Recurrence Rate — 17.3 % of subjects with recurrent hernia

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
GORE® BIO-A® Tissue Reinforcement (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
W.L.Gore & Associates
Primary completion
Dec 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Hernia Recurrence Rate
17.3
SECONDARY
Early and Long-term Complication Rates
29.8

Summary

Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue Reinforcement when used to reinforce midline fascial closure in single-staged open complex ventral incisional hernia repair.

Eligibility Criteria

Inclusion Criteria

  • Subjects will be informed about the study, and will have read; understood and signed the informed consent and authorization to use their PHI, as applicable
  • Subjects willing and able to submit to postoperative follow-up evaluations including quality of life assessments up to 24 months after surgery
  • Subjects of either gender that are at least the age of 18 years
  • Subjects will have a Body-Mass Index (BMI) of 9 cm2 large when measured intraoperatively
  • Subjects in which the required mobility for midline fascial closure without excessive tension to reapproximate the rectus abdominis muscle intraoperatively can be achieved
  • Subjects in which one unit of GORE® BIO-A® Tissue Reinforcement will adequately reinforce the midline fascial closure with at least 4 cm of overlap laterally

Exclusion Criteria

  • Subjects who, in the surgeon's opinion, would have a difficult time comprehending or complying with the requirements of the study
  • Subjects with a BMI > 40
  • Subjects with evidence of pre-existing systemic infections
  • Subjects with cirrhosis or are currently being treated with dialysis
  • Subjects with a wound-healing disorder
  • Subjects with autoimmune disorder requiring > 10mg of a corticosteroid per day
  • Subjects who are immunocompromised such as, with HIV or transplant, or receiving chemo or radiation therapy
  • Subjects with a hernia defect < 9 cm2 large when measured intraoperatively
  • Subjects with a hernia defect requiring more than one unit of GORE® BIO-A® Tissue Reinforcement
  • Subjects in which intraoperatively there is an inability to achieve retrorectus or intraperitoneal placement of the device
  • Subjects in which a midline fascial closure without excessive tension cannot be achieved
  • Subjects in which intraoperatively their surgical field/wound is characterized either a Type 1 or Type 4 in the Table 1 in Section 12
  • Subjects in need of concomitant surgical procedures other than indicated in the protocol as acceptable
  • Subject in which their complex ventral incisional hernia repair requires more than one operation to reduce hernia and close fascia, including serial excision procedures - requiring subsequent surgery to complete their hernia repair
  • Subjects with a hernia repair requiring an emergent procedure, such as strangulated bowel
  • Subjects in which intraoperatively untreated cancer was found
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01325792). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search